Solid GT Information

A Solid subsidiary, Solid GT was founded to advance gene therapy as a disease modifying treatment for all DMD patients. Together with leaders of industry and academia, along with major organizations in the DMD space, Solid GT is developing therapeutics designed to deliver widespread expression of microdystrophin, a much smaller functional version of dystrophin, through robust delivery systems. The goal of Solid GT is to rapidly advance our lead candidate into clinical trials, leveraging the guidance and expertise of key DMD and gene therapy experts, and build a robust pipeline of additional clinical candidates and second generation treatments. Solid GT continues to build collaborations and partnerships in the gene therapy space and welcomes meaningful opportunities to advance potential therapies for DMD.